Myriad Genetics Inc (MYGN) — 分析摘要
Myriad Genetics Inc（MYGN）的市值为553.47百万美元，最近一年的营收同比增长了-1.6%。净利润率为-44.4%。当前市盈率为-1.4倍。
核心要点
- 营收同比变化-1.6%
- 净利润率-44.4%
- 市盈率-1.4倍
与IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES板块的其他公司相比，MYGN的营收增长为-1.6%，市盈率为-1.4倍。
Myriad Genetics Inc (MYGN)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -28.2x — 盈利不足以覆盖利息支出
营业利润率为 -46.9% — 经营亏损显著
净利率为 -48.2% — 亏损显著
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.
行业
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
员工人数
2,700
总部
SALT LAKE CITY, UT
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。